OBJECTIVES: To assess the effect of food on the pharmacokinetics of the anti-malarial amodiaquine (AQ, CAS 6398-98-7) and artesunate (AS, CAS 182824-33-5) and their active metabolites [desethylamodiaquine (DSA, CAS 81496-81-3) and dihydroartemisinin (DHA, CAS79352-78-6), respectively] in healthy volunteers. METHODS: In an open, two-way crossover study, 22 healthy male volunteers fasted overnight and were randomised to receive a single oral administration of 4 tablets of a fixed-dose combination containing 135 mg AQ and 50 mg AS in the absence or presence of a standardised high-fat breakfast, administered 30 min before drug administration. Blood samples were collected up to Day 10 and AQ, DSA, AS and DHA were assayed by an LC/MS/MS method. RESULTS: Relative to the fasting state, the administration of the fixed-dose combination after a high-fat breakfast resulted in delayed median Tmax values for AQ (15 min and for DSA (2.3 h). The geometric mean ratios (GMR) of fed to fasting conditions indicated increased Cmax values for AQ (GMR 1.22) (90% CI: 1.07-1.39) and DSA (GMR 1.21) (90% CI: 1.05-1.39) and increased AUC0-t values for AQ (GMR 1.59) (90% CI: 1.39-1.83) and for DSA (GMR 1.13) (90% CI: 1.04-1.24). The median Tmax values were not delayed for AS as opposed to DHA (approximately 1 h delay). The Cmax values were decreased for AS (GMR 0.36) (90% CI: 0.30-0.47) and for DHA (GMR 0.51) (90% CI: 0.44-0.60). The AUC0-t values were slightly decreased for AS (GMR 0.89) (90% CI: 0.74-1.06) and for DHA (GMR 0.93) (90% CI: 0.84-1.02). CONCLUSION: Intake of AQ and AS with a high fat meal resulted in (1) a statistically significant increase in blood levels of AQ and DSA which may affect the safety and tolerability of the study drugs and (2) a decrease in AS and DHA blood levels which may affect efficacy. These results suggest that the fixed-dose combination should not be administered with a high-fat meal.
RCT Entities:
OBJECTIVES: To assess the effect of food on the pharmacokinetics of the anti-malarial amodiaquine (AQ, CAS 6398-98-7) and artesunate (AS, CAS 182824-33-5) and their active metabolites [desethylamodiaquine (DSA, CAS 81496-81-3) and dihydroartemisinin (DHA, CAS79352-78-6), respectively] in healthy volunteers. METHODS: In an open, two-way crossover study, 22 healthy male volunteers fasted overnight and were randomised to receive a single oral administration of 4 tablets of a fixed-dose combination containing 135 mg AQ and 50 mg AS in the absence or presence of a standardised high-fat breakfast, administered 30 min before drug administration. Blood samples were collected up to Day 10 and AQ, DSA, AS and DHA were assayed by an LC/MS/MS method. RESULTS: Relative to the fasting state, the administration of the fixed-dose combination after a high-fat breakfast resulted in delayed median Tmax values for AQ (15 min and for DSA (2.3 h). The geometric mean ratios (GMR) of fed to fasting conditions indicated increased Cmax values for AQ (GMR 1.22) (90% CI: 1.07-1.39) and DSA (GMR 1.21) (90% CI: 1.05-1.39) and increased AUC0-t values for AQ (GMR 1.59) (90% CI: 1.39-1.83) and for DSA (GMR 1.13) (90% CI: 1.04-1.24). The median Tmax values were not delayed for ASas opposed to DHA (approximately 1 h delay). The Cmax values were decreased for AS (GMR 0.36) (90% CI: 0.30-0.47) and for DHA (GMR 0.51) (90% CI: 0.44-0.60). The AUC0-t values were slightly decreased for AS (GMR 0.89) (90% CI: 0.74-1.06) and for DHA (GMR 0.93) (90% CI: 0.84-1.02). CONCLUSION: Intake of AQ and AS with a high fat meal resulted in (1) a statistically significant increase in blood levels of AQ and DSA which may affect the safety and tolerability of the study drugs and (2) a decrease in AS and DHA blood levels which may affect efficacy. These results suggest that the fixed-dose combination should not be administered with a high-fat meal.
Authors: Stephanie E Reuter; Allan M Evans; Sepehr Shakib; Yvonne Lungershausen; Barbara Francis; Giovanni Valentini; Antonella Bacchieri; David Ubben; Silvia Pace Journal: Clin Drug Investig Date: 2015-09 Impact factor: 2.859
Authors: Anna Annerberg; Khin Maung Lwin; Niklas Lindegardh; Sakchai Khrutsawadchai; Elizabeth Ashley; Nicholas P J Day; Pratap Singhasivanon; Joel Tarning; Nicholas J White; François Nosten Journal: Antimicrob Agents Chemother Date: 2011-06-27 Impact factor: 5.191
Authors: Chu Xuan Anh; Marina Chavchich; Geoffrey W Birrell; Karin Van Breda; Thomas Travers; Kerryn Rowcliffe; Anton R Lord; G Dennis Shanks; Michael D Edstein Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191
Authors: Nguyen Ngoc Quang; Marina Chavchich; Chu Xuan Anh; Geoffrey W Birrell; Karin van Breda; Thomas Travers; Kerryn Rowcliffe; Michael D Edstein Journal: Am J Trop Med Hyg Date: 2018-05-03 Impact factor: 2.345
Authors: Thomas A Anyorigiya; Sandra Castel; Katya Mauff; Frank Atuguba; Bernhards Ogutu; Abraham Oduro; David Dosoo; Kwaku-Poku Asante; Seth Owusu-Agyei; Alexander Dodoo; Abraham Hodgson; Fred Binka; Lesley J Workman; Elizabeth N Allen; Paolo Denti; Lubbe Wiesner; Karen I Barnes Journal: Malar J Date: 2021-01-06 Impact factor: 2.979
Authors: Birgit Schramm; Parastou Valeh; Elisabeth Baudin; Charles S Mazinda; Richard Smith; Loretxu Pinoges; Timothy Sundaygar; Yah M Zolia; Joel J Jones; Eric Comte; Arnaud Bruneel; Michel Branger; Vincent Jullien; Gwenaelle Carn; Jean-René Kiechel; Elizabeth A Ashley; Philippe J Guérin Journal: Malar J Date: 2013-07-17 Impact factor: 2.979